Heron Therapeutics, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$82.8M
Doctors Paid
15,971
Transactions
31,937
2024 Total
$944,837
Payment Breakdown by Category
Research$71.3M (86.0%)
Consulting$6.4M (7.7%)
Food & Beverage$1.0M (1.2%)
Travel$925,880 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $71.3M | 1,539 | 86.0% |
| Consulting Fee | $6.4M | 1,777 | 7.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 1,152 | 2.9% |
| Food and Beverage | $1.0M | 24,978 | 1.2% |
| Travel and Lodging | $925,880 | 2,478 | 1.1% |
| Current or prospective ownership or investment interest | $772,542 | 6 | 0.9% |
| Space rental or facility fees (teaching hospital only) | $14,000 | 1 | 0.0% |
| Grant | $10,000 | 1 | 0.0% |
| Education | $178.28 | 5 | 0.0% |
Payments by Type
Research
$71.3M
1,539 transactions
General
$11.6M
30,398 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia | $11.0M | 0 | 244 |
| Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2) | $10.9M | 0 | 131 |
| Bunionectomy Study for Postoperative Analgesia (EPOCH 1) | $9.2M | 0 | 103 |
| Phase 2B Upper Extremity Nerve Block Study | $7.7M | 0 | 38 |
| Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen | $4.1M | 0 | 107 |
| Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery | $4.0M | 0 | 30 |
| Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy | $3.0M | 0 | 41 |
| Herniorrhaphy Study for Opioid Elimination | $2.9M | 0 | 243 |
| Phase 2 Herniorrhaphy Study for Opioid Elimination | $2.8M | 0 | 32 |
| A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy | $2.6M | 0 | 23 |
| A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE | $2.6M | 0 | 69 |
| Dose-Escalation Study of HTX-034 Following Bunionectomy | $2.5M | 0 | 36 |
| HTX-011 in Spinal Surgery | $1.7M | 0 | 161 |
| Phase 2 Bunionectomy HTX-011 Administration Study | $1.3M | 0 | 12 |
| A Phase 4, Open-Label Study of Liposomal Bupivacaine Admixed With Bupivacaine HCl in Subjects Undergoing Total Knee Arthroplasty | $1.1M | 0 | 40 |
| Bupivacaine HCl PK and Safety in Augmentation Mammoplasty | $843,606 | 0 | 5 |
| A Randomized, Phase 4 Study of the Efficacy, Safety, and Pharmacokinetics of Bupivacaine Administered as Liposomal Bupivacaine or Continuous Infusion via Elastomeric Pump Following Unilateral Open Inguinal Herniorrhaphy | $714,176 | 0 | 8 |
| HTX-011 Administration Study in Planned Caesarean Section Procedure | $616,151 | 0 | 67 |
| Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | $509,758 | 0 | 53 |
| A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of HTX-019 Administered as an Intravenous Infusion or Injection in Healthy Subjects. | $376,559 | 0 | 2 |
| A PHASE 4, OPEN-LABEL SAFETY STUDY OF REPEAT DOSES OF SUSTOL IN ADULT SUBJECTS RECEIVING CHEMOTHERAPY | $213,022 | 0 | 24 |
| Prospective, Observational Study of the Safety and Tolerability of CINVANTI Administered as an Intravenous Infusion or Injection in Patients Receiving Emetogenic Chemotherapy for Cancer Treatment | $183,790 | 0 | 1 |
| Extended Delivery of Bupivacaine Study in Herniorrhaphy | $70,347 | 0 | 1 |
| A PHASE 2, TWO-PART, MULTICENTER STUDY OF HTX-011 IN SPINAL SURGERY | $63,300 | 0 | 20 |
| Safety Study of Repeat Doses of SUSTOL in Adults | $56,136 | 0 | 8 |
| A PHASE IV, OPEN-LABEL, RANDOMIZED, ACTIVE-CONTROLLED, SINGLE-CENTER STUDY OF ZYNRELEF FOR POSTOPERATIVE ANALGESIA AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY | $48,130 | 0 | 2 |
| The use of Zynrelef in Laparoscopic pre[1]peritoneal inguinal hernia repairs | $37,945 | 0 | 4 |
| Pediatric Postoperative Analgesia Herniorrhaphy Study | $32,328 | 0 | 4 |
| HTX-011 FOR USE IN LAPAROSCOPIC PRE-PERITONEAL INGUINAL HERNIA REPAIRS | $26,840 | 0 | 2 |
| A PHASE 3B, RANDOMIZED, OPEN-LABEL STUDY OF HTX-011 AS THE FOUNDATION OF A NON-OPIOID, MULTIMODAL ANALGESIC REGIMEN TO DECREASE OPIOID USE FOLLOWING UNILATERAL OPEN INGUINAL HERNIORRHAPHY | $25,094 | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2020 |
|---|---|---|---|---|
| Dr. Gilad Gordon, Md, MD | Internal Medicine | Boulder, CO | $869,683 | $0 |
| Sharmila Dissanaike, Md, MD | Surgical Critical Care | Lubbock, TX | $841,262 | $0 |
| Neil Clendeninn, Md, MD | Hospice and Palliative Medicine | Princeville, HI | $636,321 | $0 |
| Dr. Scott Hacker, M.d, M.D | Specialist | La Mesa, CA | $534,690 | $0 |
| Dr. Mark Marino | Internal Medicine | Carlsbad, CA | $470,110 | $0 |
| Dr. Randy Robbins, M.d, M.D | Anesthesiology | Plano, TX | $436,252 | $0 |
| Dr. Alan Rechter, Md, MD | Orthopaedic Surgery | Houston, TX | $421,585 | $0 |
| Ralph Boccia, M.d, M.D | Medical Oncology | Bethesda, MD | $340,895 | $0 |
| Rudolph Navari, M.d, M.D | Internal Medicine | Birmingham, AL | $280,227 | $0 |
| Dr. Alexander Sah, Md, MD | Adult Reconstructive Orthopaedic Surgery | Fremont, CA | $233,264 | $0 |
| Dr. Eugene Viscusi, M.d, M.D | Anesthesiology | Philadelphia, PA | $228,752 | $0 |
| Jeffrey Kittrelle, Md, MD | Clinical Pharmacology | San Diego, CA | $205,500 | $0 |
| Phillip Shadduck, Md, MD | Surgery | Durham, NC | $201,906 | $0 |
| Unknown Provider | — | — | $168,501 | $0 |
| Dr. Jay Mason, M.d, M.D | Cardiovascular Disease | Reno, NV | $162,976 | $0 |
| Dr. Mark Mainous, Md, MD | Surgical Critical Care | Shreveport, LA | $112,671 | $0 |
| Dr. Timothy Beard, M.d,, M.D, | Specialist | Bend, OR | $109,802 | $0 |
| Russell Tigges, Md, MD | Adult Reconstructive Orthopaedic Surgery | Poughkeepsie, NY | $105,760 | $0 |
| Scott Sigman, Md, MD | Orthopaedic Surgery | North Chelmsford, MA | $95,197 | $0 |
| Tong Gan, M.d, M.D | Anesthesiology | Houston, TX | $92,175 | $0 |
| Harold Minkowitz, M.d, M.D | Anesthesiology | Houston, TX | $89,737 | $0 |
| Chad Brummett, Md, MD | Anesthesiology | Ann Arbor, MI | $85,930 | $0 |
| Andrew Noble, M.d, M.D | Adult Reconstructive Orthopaedic Surgery | Palm Beach Gardens, FL | $83,845 | $0 |
| Dr. Loren Laine, M.d, M.D | Gastroenterology | West Haven, CT | $82,665 | $0 |
| Nashat Gabrail, M.d, M.D | Specialist | Canton, OH | $78,064 | $0 |
Ad
Top Products
- HTX-011 $64.2M
- Zynrelef $7.9M
Associated Products (10)
Payment Categories
- Food & Beverage $1.0M
- Consulting $6.4M
- Travel & Lodging $925,880
- Research $71.3M
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. has made $82.8M in payments to 15,971 healthcare providers, recorded across 31,937 transactions in the CMS Open Payments database. In 2024, the company paid $944,837. The top product by payment volume is HTX-011 ($64.2M).
Payments were distributed across 170 medical specialties. The top specialty by payment amount is Internal Medicine ($1.8M to 292 doctors).
Payment categories include: Food & Beverage ($1.0M), Consulting ($6.4M), Research ($71.3M), Travel & Lodging ($925,880).
Heron Therapeutics, Inc. is associated with 10 products in the CMS Open Payments database, including HTX-011, Zynrelef, and SUSTOL.